Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment

A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02098941

Enrollment

2500

Registered

2014-03-28

Start date

2014-03-31

Completion date

2014-12-31

Last updated

2014-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

topiramate, oxcarbazepine, levetiracetam, retention rate

Brief summary

The Objective of this study is to compare 2-year retention rate of topiramate, levetiracetam and oxcarbazepine in a long term epilepsy treatment.

Detailed description

Primary objective The Objective of this study is to compare 2-year retention rate of topiramate, levetiracetam and oxcarbazepine in a long term epilepsy treatment. Secondary objective The main secondary objective of this study is to evaluate confounding factors associated with retention rate of topiramate compared with other anticonvulsants. 1. Baseline characteristics * Seizure Type * Gender * Age of onset 2. Treatment regimen * Number of concomitant medication * Type of drug combination * Final target dose * Titration speed Other secondary objectives The other secondary objectives of this study are to compare followings by each medication: * Rate of seizure reduction (≥75%, ≥50%) * Rate of seizure freedom

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 95 Years

Healthy volunteers

Inclusion criteria

* Subjects who began their treatment with topiramate, levetiracetam or oxcarbazepine as mono or add-on therapy with conventional drugs. * Subjects who are with partial or generalized epilepsy

Exclusion criteria

* Subjects who administered combination therapy in topiramate, levetiracetam or oxcarbazepine * Subjects who have past experience of surgery for epilepsy treatment * Subjects who were not followed up for at least 1 year

Design outcomes

Primary

Measure	Time frame	Description
Retention rate of topiramate, levetiracetam and oxcarbazepine during 24 months of treatment	24months	Overall retention rates of three treatment groups at two years will be presented in patient number (% of continuation or discontinuation).

Secondary

Measure	Time frame	Description
Evaluate the confounding factors affecting the retention rate	24 months	-Confounding factors associated with retention rate : Seizure Type, gender, age, treatment regimen, number of concomitant medication, type of drug combination, final target dose, titration speed
Evaluate the response rate through seizure reduction (≥75%, ≥50%) in 2-year treatment with each antiepileptic drugs (topiramate, levetiracetam, oxcarbazepine)	24 months	—

Other

Measure	Time frame
main reasons of drug discontinuation	24 months

Countries

South Korea

Contacts

Primary ContactSang kun Lee, MD, PhD

sangkun2923@gmail.com

Backup ContactJung-won Shin, MD

limitsum@gmail.com

Outcome results